|BBI-503游离态|CsnPharm

CAS No.: 1129403-56-0

Amcasertib Catalog No. CSN18654

Synonyms: BBI503

Amcasertib is an inhibitor of cancer stem cells (CSCs) with growth inhibition IC50s of 100-250 nM for HT-29 and MDA-MB-231 cancer cells. It also inhibits EGFR, C-MET, HER2, and PDGFRα in vitro without reducing global tyrosine kinase activity.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Amcasertib is an orally administered investigational agent designed to inhibit cancer stem cell pathways, it is claimed to inhibit Nanog and other CSC pathways by targeting kinases with potential anticancer activity.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02232620	Gastrointestinal Stromal Tumor... more >>s Collapse <<	Phase 2	Active, not recruiting	December 2019	Canada, Ontario ... more >> Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Collapse <<
NCT02279719	Hepatocellular Carcinoma	Phase 1 Phase 2	Active, not recruiting	-	-
NCT02232633	Hepatocellular Carcinoma ... more >> Cholangiocarcinoma Collapse <<	Phase 2	Active, not recruiting	-	Canada, Alberta ... more >> University of Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, Ontario The Ottawa Hospital Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Princess Margaret Hospital Toronto, Ontario, Canada Collapse <<

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.8529 mL
- 9.2646 mL
- 18.5292 mL
- 5 mM
- 0.3706 mL
- 1.8529 mL
- 3.7058 mL
- 10 mM
- 0.1853 mL
- 0.9265 mL
- 1.8529 mL

技术信息

CAS号

1129403-56-0

储存条件

粉末: Sealed in dry,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C31H33N5O2S

运输

蓝冰

分子量

539.69

别名

BBI503

溶解度

DMSO	14.0 mg/mL (25.9 mM)
Water	Insoluble
Ethanol	1.0 mg/mL (1.9 mM)

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02232620	Gastrointestinal Stromal Tumor... more >>s Collapse <<	Phase 2	Active, not recruiting	December 2019	Canada, Ontario ... more >> Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Collapse <<
NCT02279719	Hepatocellular Carcinoma	Phase 1 Phase 2	Active, not recruiting	-	-
NCT02232633	Hepatocellular Carcinoma ... more >> Cholangiocarcinoma Collapse <<	Phase 2	Active, not recruiting	-	Canada, Alberta ... more >> University of Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, Ontario The Ottawa Hospital Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Princess Margaret Hospital Toronto, Ontario, Canada Collapse <<
NCT02483247	Cancer	Phase 1 Phase 2	Active, not recruiting	-	United States, Indiana ... more >> Parkview Research Center Fort Wayne, Indiana, United States Indiana University Health Goshen Goshen, Indiana, United States, 46526 Indiana University -Ball Indianapolis, Indiana, United States Indiana University-SCC Indianapolis, Indiana, United States United States, Louisiana Louisiana State Univesity New Orleans, Louisiana, United States United States, Virginia US Oncology Research Fairfax, Virginia, United States Canada, Ontario Ottawa Hospital Research Institute Ottawa, Ontario, Canada Princess Margaret Cancer Centre Toronto, Ontario, Canada Collapse <<
NCT02432690	Cancer Ovaria... more >>n Cancer Collapse <<	Phase 2	Active, not recruiting	-	United States, Minnesota ... more >> Mayo Clinic Rochester, Minnesota, United States, 55905 Collapse <<
NCT02232646	Urologic Malignancies ... more >> Renal Cell Carcinoma Urothelial Carcinoma Collapse <<	Phase 2	Withdrawn(Low feasibility)	-	-

Amcasertib Catalog No. CSN18654

靶点选择性

请登录您的专属账户

确认信息